Association Analysis Between Catechol-O-Methyltransferase Expression and Cognitive Function in Patients with Schizophrenia, Bipolar Disorder, or Major Depression
- PMID: 33654399
- PMCID: PMC7910219
- DOI: 10.2147/NDT.S286102
Association Analysis Between Catechol-O-Methyltransferase Expression and Cognitive Function in Patients with Schizophrenia, Bipolar Disorder, or Major Depression
Abstract
Introduction: Schizophrenia, bipolar disorder (BD), and major depressive disorder are three common mental disorders. Although their diagnosis and treatment differ, they partially overlap.
Methods: To explore the similarities and characteristics of these three psychiatric diseases, an intelligence quotient (IQ) assessment was performed to evaluate cognitive deficits. Relative catechol-O-methyltransferase (COMT) expression in peripheral blood mononuclear cells was examined in all three groups compared with healthy controls (HCs).
Results: The results indicated that patients with any of the three psychiatric diseases presented IQ deficits, and that the first-episode schizophrenia (FES) group had even lower cognitive function than the other two groups. The relative COMT expression decreased in the FES group and increased in the BD group compared with the HC group. The correlation analysis of COMT expression level and IQ scores showed a positive correlation between relative COMT expression and full-scale IQ in the HC group. However, this correlation disappeared in all three psychiatric diseases studied.
Conclusion: In conclusion, this cross-disease strategy provided important clues to explain lower IQ scores and dysregulated COMT expression among three common mental illnesses.
Keywords: BD; COMT; FES; IQ; MDD; bipolar disorder; catechol-O-methyltransferase; first-episode major depressive disorder; first-episode schizophrenia; intelligence quotient.
© 2021 Ni et al.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures

Similar articles
-
Intelligence decline across major depressive disorder, bipolar disorder, and schizophrenia.CNS Spectr. 2021 Mar 18:1-7. doi: 10.1017/S1092852921000298. Online ahead of print. CNS Spectr. 2021. PMID: 33731244
-
Association between catechol-O-methyltransferase genetic variation and functional connectivity in patients with first-episode schizophrenia.Schizophr Res. 2018 Sep;199:214-220. doi: 10.1016/j.schres.2018.04.023. Epub 2018 May 3. Schizophr Res. 2018. PMID: 29730044
-
Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects.J Psychiatr Res. 2014 Sep;56:28-35. doi: 10.1016/j.jpsychires.2014.04.019. Epub 2014 May 9. J Psychiatr Res. 2014. PMID: 24853458
-
The impact of COMT polymorphisms on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.J Affect Disord. 2019 Jan 15;243:545-551. doi: 10.1016/j.jad.2018.08.009. Epub 2018 Aug 8. J Affect Disord. 2019. PMID: 30146088 Review.
-
Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).CNS Neurol Disord Drug Targets. 2012 May;11(3):264-72. doi: 10.2174/187152712800672445. CNS Neurol Disord Drug Targets. 2012. PMID: 22483292 Review.
Cited by
-
Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer's Disease and Mild Cognitive Impairment.Biomedicines. 2023 Jan 17;11(2):235. doi: 10.3390/biomedicines11020235. Biomedicines. 2023. PMID: 36830773 Free PMC article.
-
Combinations of genes at the 16p11.2 and 22q11.2 CNVs contribute to neurobehavioral traits.PLoS Genet. 2023 Jun 2;19(6):e1010780. doi: 10.1371/journal.pgen.1010780. eCollection 2023 Jun. PLoS Genet. 2023. PMID: 37267418 Free PMC article.
-
Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders.Neurosci Appl. 2023 Mar 20;2:101125. doi: 10.1016/j.nsa.2023.101125. eCollection 2023. Neurosci Appl. 2023. PMID: 40655966 Free PMC article. Review.
References
-
- Wood MD, Wren PB. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. Prog Brain Res. 2008;172:213–230. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous